Figure S2 from Phase I Clinical Trial of Combination Propranolol and Pembrolizumab in Locally Advanced and Metastatic Melanoma: Safety, Tolerability, and Preliminary Evidence of Antitumor Activity
| Autor: | Marc S. Ernstoff, Elizabeth A. Repasky, Hemn Mohammadpour, Igor Puzanov, Mark J. Bucsek, Joseph J. Drabick, Pauline Funchain, Suzanne Stack, Maria Levis, Carlos D. Cedeno, Paul K. Wallace, Joseph D. Tario, Cheryl Allen, Erik S. Knudsen, Agnieszka K. Witkiewicz, Wenyan Ji, Kristopher Attwood, Manu R. Pandey, Shipra Gandhi |
|---|---|
| Rok vydání: | 2023 |
| Popis: | Biomarker changes over time. A, Variations in chemokines IP-10, eotaxin and TNF-β in pg/ml. B, Variation in CD8+T-cells, m-MDSC, PMN-MDSC, regulatory T-cells (Tregs) expressed as percentage of total CD45+ cells, ratio of CD8+/ PMN-MDSC. C, Relative changes in peripheral blood cells (PMN-MDSC, CD8+ T-cell, CD8+ T cells/T-reg) and IL-12p70. Dose level 1 is propranolol 10 mg BID, dose level 2 is propranolol 20 mg BID and dose level 3 is propranolol 30 mg BID. Asterix show significant values at different time points compared to baseline in different dose levels. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|